Navigation Links
Volcano Corporation Schedules Third Quarter Conference Call, Webcast
Date:10/28/2008

SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today announced that it will report its operating results for the third quarter and first nine months of fiscal 2008 on Wednesday, November 5.

The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Standard Time (5 p.m. Eastern Standard Time), Wednesday, November 5, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer.

The teleconference can be accessed by calling (719) 325-4761, passcode 8632414. Please dial in 10-15 minutes prior to the beginning of the call. The webcast will be available through the company's website at http://www.volcanocorp.com.

A replay of the conference call will be available through Wednesday, November 12, at (719) 457-0820, passcode 8632414, and via the company's website.

About Volcano Corporation

Volcano Corporation (NASDAQ: VOLC) offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart disease and guide optimal therapies. The company's intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be integrated directly into virtually any mod
'/>"/>

SOURCE Volcano Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
2. Volcano Corporation Announces Pricing of Common Stock Offering
3. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
4. Volcano Announces Closing of CardioSpectra Acquisition
5. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
6. Volcano Announces FDA 510(k) Clearance of Revolution Rotational Catheter and FFR for the s5i Integrated IVUS Console
7. Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast
8. Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
9. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
10. Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter
11. Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 DTS Language Services, ... Online Web Portal for Life Science organizations who need document ... the subject matter of their documents in advance with a ... reduce time-to-delivery of translations, often a critical factor in clinical ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... 14, 2014  3D Communications, a leading provider of strategic communications services ... media events in the United States and ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as Associate ...
(Date:1/14/2014)... and BETHESDA, Md. , ... joining together with two institutes from the National Institutes ... tools for bringing safer, more effective treatments to patients ... National Center for Advancing Translational Sciences (NCATS) and the ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
...  Frank A. Critz, M.D., founder and medical director of Radiotherapy ... welcome this April when he returns to Fulton, Miss.  for ... will be April 14, 2012 at the Holiday Inn Express ... until 3 p.m., and lunch will be served. ...
... 20, 2012 The American College of Radiology (ACR) ... Donald P. Rosen, MD, chief executive officer of ACR ... research organization (CRO) and for-profit subsidiary of the ACR. ... of experience in radiology, including contract research and business ...
... Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm ... Virus (HIV) infections, announced today that it has ... pursuant to which the Company has agreed to ... stock at an aggregate purchase price of approximately ...
Cached Biology Technology:Radiotherapy Clinics of Georgia's Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award 2Imaging Contract-Research Pioneer, Donald P. Rosen, MD, Named CEO of ACR Image Metrix™ 2GeoVax Announces Private Placement of $2.2 Million 2GeoVax Announces Private Placement of $2.2 Million 3GeoVax Announces Private Placement of $2.2 Million 4
(Date:4/17/2014)... Calif. One day about eight years ago, ... California, Riverside, and her father were on a field trip ... upon an orchid they had never seen before. , Unable ... on orchids. The orchid turned out to be an ... Lophiaris silverarum . , "Lophiaris" is the genus name, ...
(Date:4/17/2014)... on a novel method to help kidney stone ... effective treatment possible., Kidney stones represent a major ... If left untreated, apart from being particularly painful, ... complications. In many patients treated successfully, stone recurrence ... pathological approach to diagnosis and treatment needs to ...
(Date:4/17/2014)... Gene expression is the process whereby the genetic ... products, such as proteins, which have numerous different ... as an important intermediary during gene expression, by ... molecular mechanisms involved in manufacturing proteins. , ... mRNA molecules present in an organism at a ...
Breaking Biology News(10 mins):Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3Rapid and accurate mRNA detection in plant tissues 2
... protein kinase is an essential regulator of cytoskeletal ... whether Rho kinase regulates microtubule remodeling or the ... remains unclear. By using the ROCK inhibitor, Y-27632, ... colleagues from First Affiliated Hospital of Jinan University ...
... know about MyPyramid the triangle depicting how many servings ... - but who knows about MyPlate - the circle showing ... 2011 by the United States Department of Agriculture (USDA) to ... a simple, colorful icon that prompts us to think about ...
... cell-based gene therapy holds promise for the treatment of devastating ... approach have been unclear. In a study online December 26th ... published by Cell Press, researchers evaluated a patient with a ... years after he had undergone a gene therapy procedure as ...
Cached Biology News:Who is using MyPlate? 2Gene therapy for human skin disease produces long-term benefits 2